Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03346499 · ClinicalTrials.gov registry record · Phase 1
Adoptive Transfer of Haploidentical Natural Killer Cells and IL-2
A Phase 1 study, sponsored by University of Minnesota.
- Completed
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT03346499 is a Phase 1 study that has completed, run by University of Minnesota. The registered enrollment target is 4 participants.
The verdict
NCT03346499, a Phase 1 study, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
This is a pilot study of the infusion of haploidentical NK cells with IL-2 in 5 HIV+ individuals who are on stable ART with full HIV suppression.
Interventions
- BIOLOGICAL NK cells and IL-2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2017-03-09 |
| Est. Completion | 2018-11-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03346499
The ClinicalTrials.gov registry entry for NCT03346499 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NK cells and IL-2 is the first listed.
NCT03346499 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03346499 about?
NCT03346499 is a clinical study titled "Adoptive Transfer of Haploidentical Natural Killer Cells and IL-2". This is a pilot study of the infusion of haploidentical NK cells with IL-2 in 5 HIV+ individuals who are on stable ART with full HIV suppression.
What is the current status of trial NCT03346499?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2017-03-09. Estimated completion is 2018-11-13.
What interventions are being tested in trial NCT03346499?
The interventions under investigation include: NK cells and IL-2 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03346499?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.